Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Phase III NCT02468024

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer — Recruiting • Phase III • Oncology • NCT02468024.

📅 16 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase III
NCT ID
NCT02468024
Sponsor
University of Texas Southwestern Medical Center
Start
2015-07
ClinicaliQ Trial Snapshot
  • JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer — Recruiting • Phase III • Oncology • NCT02468024.
  • Sponsor: University of Texas Southwestern Medical Center.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

Eligibility Snapshot
  • 0 Inclusion Criteria 1.1 Age > 18 years. 1.2 ECOG/Zubrod performance status (PS) 0, 1, or 2 (reference Appendix C). 1.3 Radiographic findings consistent with non-small cell lung cancer, including lesions with ground glass opacities with a solid component of 50% or greater. 1.4 The primary tumor in the lung must be biopsy confirmed non-small cell lung cancer within 180 days prior to randomization. 1.5 Tumor ≤ 4 cm maximum diameter, including clinical stage IA and selected IB by PET or PET integrated with a simultaneous CT scan (PET-CT) of the chest and upper abdomen performed within 180 days prior to randomization (reference Appendix A & B). Repeat imaging within 90 days prior to randomization is recommended for re-staging but is not required based on institutional norms. 1.6 All clinically suspicious mediastinal N1, N2, or N3 lymph nodes (> 1 cm short-axis dimension on CT scan and/or positive on PET scan) confirmed negative for involvement with NSCLC by one of the following methods: mediastinoscopy, anterior mediastinotomy, EUS/EBUS guided needle aspiration, CT-guided, video-assisted thoracoscopic or open lymph node biopsy within 180 days of randomization. 1.7 Tumor verified by a thoracic surgeon to be in a location that will permit sublobar resection.…

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer
Oncology · 06 May 2026
Test for BRAF V600E mutation in patients with advanced NSCLC before considering encorafenib plus binimetinib, as this combination is only recommended for…
View guideline →
Guideline
2023 ESMO Clinical Practice Guidelines: Metastatic Non-Small Cell Lung Cancer
Oncology · 30 Mar 2026
Covers diagnostic workup and molecular profiling for metastatic non-small cell lung cancer (NSCLC) • Provides treatment algorithms based on biomarker status (EGFR,…
View guideline →
Guideline
Lung Cancer: Diagnosis and Management (NICE NG122)
Oncology · 25 Mar 2026
Arrange urgent chest CT within 2 weeks for patients with suspected lung cancer via 2-week wait referral pathway Perform EGFR mutation testing…
View guideline →
Clinical Brief
MPs call for sunbed advertising ban to help prevent skin cancer
Oncology · BBC Health · 13 May 2026
A cross-party parliamentary report identifies that most skin cancer cases are preventable, supporting calls for stricter regulation of sunbed advertising as a…
View brief →
Guideline
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment
Oncology · 07 May 2026
Zanidatamab is recommended by NICE as an option for HER2-positive advanced biliary tract cancer only after 1 or more prior lines of…
View guideline →
Guideline
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)
Oncology · 17 Mar 2026
I appreciate your request, but I need to be transparent: the content provided only includes the title, metadata, and editorial notes -…
View guideline →